The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
 
Michael Cecchini
Honoraria - AstraZeneca
 
Patricia LoRusso
Leadership - Agios; Five Prime Therapeutics; Halozyme; Roche/Genentech
Honoraria - Genentech/Roche
Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; CytomX Therapeutics; Genentech; Genentech; Genmab; Glenmark; Ignyta; Menarini; Novartis; Omniox; Takeda
Research Funding - Alexion Pharmaceuticals; Boehringer Ingelheim; Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer; Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
Yu Shyr
Consulting or Advisory Role - Aduro Biotech; Janssen Research & Development; Novartis; Roche/Genentech
 
S. Percy Ivy
No Relationships to Disclose
 
Jeffrey Sklar
No Relationships to Disclose
 
Kirsten Dooley
No Relationships to Disclose
 
Jill Lacy
Consulting or Advisory Role - Celgene; KeyQuest Health; Navigant Consulting; Sirtex Medical
Travel, Accommodations, Expenses - Lilly